Ask AI
HER2+ mBC Decision Support Tool
Interactive Decision Support Tool: Expert Treatment Guidance for HER2-Positive Metastatic Breast Cancer

Released: July 24, 2025

About This Tool & Disclaimer

Interactive Decision Support Tool: Expert Treatment Guidance for HER2-Positive Metastatic Breast Cancer

Clinical Care Options, LLC, is grateful to Shipra Gandhi, MD, MS; Reshma Mahtani, DO; Laura Spring, MD; Erica L. Mayer, MD, MPH; FASCO, and Heather McArthur, MD, MPH, FASCO; who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in July 2025 and reflects the guidelines available at that time.

The goal of this tool is to educate healthcare professionals on making optimal treatment choices for anti-HER2 therapy in patients with HER2-positive metastatic breast cancer.

A series of questions allow the user to select individual patient characteristics that are necessary to consider when making management choices. These characteristics included prior receipt of adjuvant or neoadjuvant therapy for localized disease, previous treatment(s) for metastatic or systemic disease, and HR status.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with HER2-positive metastatic breast cancer. Other considerations that are not included in the algorithm of this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate.

This tool assumes that the patient is an adult diagnosed with HER2-positive metastatic breast cancer for whom anti-HER2 therapy is being considered or has started. The tool also assumes that there are no other features or specific comorbidities that would materially affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display guideline and expert recommendations for that specific patient case.

For additional information and resources on best practices in the management of patients HER2-positive metastatic breast cancer, visit the program page, where you can find free educational content such as an on-demand webcast, downloadable slidesets, an infographic on treatment options, and podcasts on the treatment landscape and unmet needs in this disease setting.

This program is supported by an educational grant from AstraZeneca and Daiichi Sankyo, Inc.

Produced in collaboration with the SmartPatients advocacy group.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Shipra Gandhi, MD, MS: consultant/advisor/speaker: AstraZeneca, Hologic, Novartis, Roche.

Reshma Mahtani, DO: consultant/advisor: Agendia, AstraZeneca, Arvinas, Bicycle Therapeutics, Daiichi Sankyo, Genentech, Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, Stemline.

Laura Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Precede, Seagen; researcher: AstraZeneca, Genentech, Gilead, Lilly, Merck; other (travel support): Lilly.

Erica L. Mayer, MD, MPH, FASCO: consultant/advisor/speaker: AstraZeneca, Lilly, Novartis.

Heather McArthur, MD, MPH, FASCO: consultant/advisor/speaker: ALX, AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Merck, Novartis, Pfizer, Stemline.

Based on the characteristics entered, the tool will display expert-based recommendations for that specific patient case.

© 2025 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Treatment Guidance for HER2-Positive Metastatic Breast Cancer” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal systemic treatment selection for patients with HER2-positive metastatic breast cancer. The information provided in the tool is based on the latest guideline recommendations and expert guidance of Shipra Gandhi, MD, MS; Reshma Mahtani, DO; Laura Spring, MD; Erica L. Mayer, MD, MPH, FASCO; and Heather McArthur, MD, MPH, FASCO.

The material published by Clinical Care Options (CCO) reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: Expert Treatment Guidance for HER2-Positive Metastatic Breast Cancer” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. CCO provides this information on an as-is basis. This disclaimer applies to all material published by CCO including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2025 Clinical Care Options, LLC. All rights reserved.

Program Content